|Printable version||E-mail this to a friend|
EMA Workshop: working towards new therapies for spinal muscular atrophy
The event will be broadcast live on 11 November
The European Medicines Agency (EMA), Spinal muscular atrophy (SMA) Europe and the TREAT-Neuromuscular diseases (NMD) network are holding a one-day workshop to discuss, support and advance the development of therapies for the treatment of spinal muscular atrophy (SMA). SMA Europe and TREAT-NMD network are two non-profit organisations that bring together patients and academics from Europe and beyond to progress research into SMA and facilitate the development of new therapies.
The workshop will take place at EMA’s premises in London on 11 November 2016, starting at 09:00.
SMA is a rare genetic disease that affects the control of muscle movement. It is caused by a loss of specialised nerve cells, called motor neurons, which results in weakness and wasting (atrophy) of muscles used for activities such as crawling, walking, sitting up, and controlling head movement. Children born with the most serious form of the disease rarely survive beyond the age of two because of severe breathing problems.
At present there is no cure for SMA. Available treatments focus on managing symptoms and preventing complications. However, new therapies are currently being developed and SMA might become one of the first inherited neurological diseases to be successfully treated. A number of experimental therapies are currently being evaluated in early clinical trials and EMA has provided scientific advice to medicine developers on the appropriate tests and studies to be used in the development of medicines for SMA a number of times in the past few years.
The workshop will convene key stakeholders – patients, doctors, industry representatives, researchers and regulators – to take stock of the latest scientific developments in the area and discuss ways of developing therapies for the treatment of SMA. Topics for discussion will include an overview of the disease, the pharmacology of the molecules under investigation, natural history data, clinical outcome measures and potential use of biomarkers in drug development.
- Agenda - EMA - Spinal muscular atrophy workshop (07/11/2016)
Latest News from
EU and Germany reach agreement on a fair and non-discriminatory road charging scheme02/12/2016 16:27:00
After years of discussions between the EC and the German authorities, both parties agreed on a solution to put an end to the legal dispute over the planned introduction of a road charge for passenger cars in Germany.
European fund for sustainable development: Council agrees negotiating position02/12/2016 16:10:00
On 1 December 2016, the Permanent Representatives Committee (Coreper) agreed on the Council's negotiating position on the regulation on the European fund for sustainable development (EFSD) and establishing the EFSD guarantee and the EFSD guarantee fund. The text will be presented for adoption to the Council in December 2016.
‘Avalanche’ network dismantled in international cyber operation02/12/2016 15:37:00
After more than four years of investigation, the Public Prosecutor’s Office Verden and the Lüneburg Police (Germany), in close cooperation with the United States Attorney’s Office for the Western District of Pennsylvania, the Department of Justice and the FBI, Eurojust, Europol and global partners, dismantled an international criminal infrastructure platform known as ‘Avalanche’.
EC code of conduct: MEPs call for detailed declarations of interest02/12/2016 15:05:00
The EC should revise its code of conduct for Commissioners, to ensure that their declarations of interests give a complete picture of the financial situation and activities of a Commissioner and his or her family, said MEPs in a non-binding resolution voted on Thursday. The “cooling off” period for ex-Commissioners should be prolonged to 36 months, they added.
EC adopts rules to strengthen regulation of commodities markets02/12/2016 14:15:00
The EC has taken steps to strengthen the regulation of commodities markets & curb price speculation. It also ensures that firms active on these markets are regulated appropriately. The package completes the rulebook of secondary measures under the revised Markets in Financial Instruments Directive, known as MIFID II, and gives market participants time to prepare for its application, as of 3 January 2018.